



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 8, 2004

Signature: 

(Mabeela R. McMillian, Ph.D.)

Docket No.: 28967/35255B
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ferrell et al.

Application No.: 10/661,740

Filed: September 12, 2003

Art Unit: 1632

For: SCREENING AND THERAPY FOR
LYMPHATIC DISORDERS INVOLVING
THE FLT4 RECEPTOR TYROSINE KINASE
(VEGFR-3)

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The applicant requests that the documents listed on the attached Form PTO-1449 (Modified) be made of official record in the above-identified application and considered by the Examiner. Copies of documents A1-A10, B1-B8 and C1-C109 have been previously submitted to the Patent Office in prior application U.S. Serial No. 09/375,248 from which priority is claimed under 35 U.S.C. §120. However, copies of these documents will be resubmitted at the Examiner's request. Copies of documents A11-A12 and C110-C112 are enclosed herewith.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This Information Disclosure Statement is submitted before the receipt of an Office Action on the merits of the above-identified application and consequently should be


Application No.: 10/661,740

Docket No.: 28967/35255B

considered by the Patent Office without payment of a fee. See 37 C.F.R. §1.97(b). However, please charge any necessary fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855. A copy of this paper is enclosed herewith.

Dated: January 8, 2004

Respectfully submitted,

By 

Nabeela R. McMillian, Ph.D.

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN LLP


233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 28967/35255B	Serial No. 10/661,740
INFORMATION DISCLOSURE STATEMENT		Applicant Ferrell et al.	
		Filing Date September 12, 2003	Group 1632

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,002,867	03/26/91	Macevicz, S.C.	435	6	
	A2	5,143,854	09/01/92	Pirrung, <i>et al.</i>	436	518	
	A3	5,202,231	04/13/93	Drmanac, <i>et al.</i>	435	6	
	A4	5,521,065	05/28/96	Whiteley, <i>et al.</i>	435	6	
	A5	5,631,237	05/20/97	Dzau, <i>et al.</i>	514	44	
	A6	5,776,755	07/07/98	Alitalo, <i>et al.</i>	435	194	
	A7	5,792,453	08/11/98	Hammond, <i>et al.</i>	424	93.21	
	A8	5,837,832,	11/17/98	Chee, M. <i>et al.</i>	536	22.1	
	A9	6,040,157	3/21/00	Hu, <i>et al.</i>	435	69.4	
	A10	2003/0028007	2/6/03	Hu, <i>et al.</i>	536	23.5	
	A11	6,130,071	10/10/00	Alitalo <i>et al.</i>	435	69.4	
	A12	6,171,799	01/09/01	Skibbens <i>et al.</i>	435	7.1	

FOREIGN PATENT DOCUMENTS							
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	B1	WO 98/33917	08-06-98	PCT			
	B2	WO 98/07832	02-26-98	PCT			
	B3	WO 97/05250	2-13-97	PCT			
	B4	WO 01/51075	7-19-01	PCT			
	B5	WO 99/46364	9-16-99	PCT			
	B6	WO 02/29087	4-11-02	PCT			
	B7	WO 02/83704	10-24-02	PCT			
	B8	WO 02/83849	10-24-02	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C1	Achen <i>et al.</i> , "Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (Flk1) and VEGF Receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci., USA</i> , 95: 548-553 (January, 1998).	
C2	Akane <i>et al.</i> , "Direct Dideoxy Sequencing of Genomic DNA by Ligation-Mediated PCR," <i>Biotechniques</i> 16: 238-241 (1994).	
C3	Aprelikova <i>et al.</i> , " <i>FLT4</i> , a Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-pter," <i>Cancer Res.</i> , 52: 746-748 (1992).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	

Form PTO-1482 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

28967/35255B

Serial No.

10/661,740

Applicant

Ferrell et al.

Filing Date

September 12, 2003

Group

1632

INFORMATION DISCLOSURE STATEMENT


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C4	Barrowman, J.A., "Gastrointestinal Lymphatics," in <i>Lymph Stasis: Pathophysiology, Diagnosis and Treatment</i> , Chapter 9, CRC Press, Boca Raton, FL, pp. 211-231 (1991).
C5	Boshart <i>et al.</i> , "A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," <i>Cell</i> , 41:521-530 (June, 1985).
C6	Boultonwood <i>et al.</i> , "Molecular Mapping of Uncharacteristically small 5q deletions in two patients with the 5q-syndrome: Delineation of the critical region on 5q and identification of a 5q-breakpoint," <i>Genomic</i> , 19(3):425-432 (1994).
C7	Browman <i>et al.</i> , "Comprehensive Human Genetic Maps: Individual and Sex-Specific Variation in Recombination," <i>Am. J. Hum. Genetic.</i> , 63:861-869 (1998).
C8	Campbell-Beggs <i>et al.</i> , "Chyloabdomen in a neonatal foal," <i>Veterinary Record</i> , 137: 96-98 (July, 1995).
C9	Castenholz, A., "Structure of Initial and Collecting Lymphatic Vessels," in <i>Lymph Stasis: Pathophysiology, Diagnosis, and Treatment</i> , Chapter 2, CRC Press: Boca Raton, FL, pp.15-42 (1991).
C10	Dale, R.F., "The Inheritance of Primary Lymphoedema," <i>J. Med. Genet.</i> , 22: 274-278 (1985).
C11	Davis <i>et al.</i> , "Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression," <i>Hum. Gene Ther.</i> , 4:151-159 (1993).
C12	Dignam <i>et al.</i> , "Balbiani Ring 3 in Chironomus tentans Encodes a 185-kDa Secretory Protein Which is Synthesized Throughout the Fourth Larval Instar," <i>Gene</i> , 88:133-40 (1990).
C13	Douglas <i>et al.</i> , "Direct Sequencing of Double-Stranded PCR Products Incorporating a Chemiluminescent Stection Procedure," <i>Biotechniques</i> , 14:824-828 (1993).
C14	Drmanac, S. <i>et al.</i> , "Accurate sequencing by hybridization for DNA diagnostics and individual genomics," <i>Nature Biotechnology</i> , 16: 54-58 (January, 1998)
C15	Dumont <i>et al.</i> , "Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3," <i>Science</i> , 282: 946-949 (October, 1998).
C16	Evans, A.L. <i>et al.</i> , "Mapping of Primary Congenital Lymphedema to the 5q35.3 Region," <i>Am. J. Hum. Genet.</i> , 64:547-555 (1999).
C17	Ferrell <i>et al.</i> , "Hereditary lymphedema: evidence for linkage and genetic heterogeneity," <i>Hum. Mol. Genetics</i> , 7(13):2073-2078 (December, 1998).
C18	Fischer <i>et al.</i> , "DNA Fragments Differing by Single Base-Pair Substitutions are Separated in Denaturing Gradient Gels: Correspondence with Melting Theory," <i>Proc. Natl. Acad. Sci., USA</i> , 80: 1579-1583 (March, 1983).
C19	Fournier <i>et al.</i> , "Mutation in tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor," <i>Oncogene</i> , 11(5):921-931 (1995).
C20	Fournier <i>et al.</i> , "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling," <i>Oncogene</i> , 18(2):507-514 (January, 1999).
C21	Fox, J.C. <i>et al.</i> , "Angiogenic Gene Therapy," <i>Circulation</i> , 94:3065-3066 (1996).
C22	Galland <i>et al.</i> , "Chromosomal Localization of <i>FLT4</i> , a Novel Receptor-Type Tyrosine Kinase Gene," <i>Genomics</i> , 13: 475-478 (1992).
C23	Galland <i>et al.</i> , "The <i>FLT4</i> Gene Encodes a Transmembrane Tyrosine Kinase Related to the Vascular Endothelial Growth Factor Receptor," <i>Oncogene</i> , 8: 1233-1240 (1993).
C24	Genbank Accession No. AF014827, <i>Rattus norvegicus</i> vascular endothelial growth factor D (VEGF-D) mRNA, complete cds.
C25	Genbank Accession No. AJ000185, <i>Homo Sapiens</i> mRNA for vascular endothelial growth factor-D.

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 28967/35255B	Serial No. 10/661,740
INFORMATION DISCLOSURE STATEMENT		Applicant Ferrell et al.	
		Filing Date September 12, 2003	Group 1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C26	Genbank Accession No. CCY15837, Coturnix coturnix mRNA for vascular endothelial growth factor C.
	C27	Genbank Accession No. D89628, Mus musculus mRNA for vascular endothelial growth factor D, complete cds.
	C28	Genbank Accession No. L07296, Mus musculus receptor tyrosine kinase (FLT4) mRNA, complete cds.
	C29	Genbank Accession No. U73620 (Locus MMU73620) Mus musculus VEGF-C mRNA, complete cds.
	C30	Genbank Accession No. P35917, Vascular Endothelial Growth Factor Receptor 3 Precursor (VEGFR-3) (Tyrosine-Protein Kinase Receptor FLT4).
	C31	Genbank Accession No. S66407, FLT4 = receptor tyrosine kinase isoform FLT4 long {3' region, alternatively spliced} [human, mRNA Partial, 216 nt].
	C32	Genbank Accession No. X68203, H. sapiens mRNA for FLT4, class III receptor tyrosine kinase.
	C33	<i>Genetic variants and strains of the laboratory mouse</i> , 2nd ed., New York: Oxford University Press, p. 70 (1989).
	C34	Gnatenko <i>et al.</i> , "Characterization of Recombinant Adeno-Associated Virus-2 as a Vehicle for Gene Delivery and Expression into Vascular Cells," <i>J. Investig. Med.</i> , 45: 87-98 (1997).
	C35	Greenlee <i>et al.</i> , "Developmental Disorders of the Lymphatic System," <i>Lymphology</i> , 26:156-168 (1993).
	C36	Holmes <i>et al.</i> , "Hereditary Late-Onset Lymphedema," <i>Pediatrics</i> 61:575-579 (1978).
	C37	Isner <i>et al.</i> , "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," <i>Circulation</i> , 91: 2687-2692 (1995).
	C38	Isner <i>et al.</i> , "Arterial Gene Therapy for Restenosis," <i>Human Gene Therapy</i> , 7: 989-1011 (May, 1996).
	C39	Jabs <i>et al.</i> , "A Mutation in the Homeodomain of the Human MSX2 Gene in a Family Affected with Autosomal Dominant Craniosynostosis," <i>Cell</i> , 75:443-450 (November, 1993).
	C40	Jeltsch <i>et al.</i> , "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," <i>Science</i> , 276:1423-1425 (May, 1997).
	C41	Joukov <i>et al.</i> , "A Novel Vascular Endothelial Growth Factor, VEGF-C, is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," <i>EMBO J.</i> , 15:290-298 (1996).
	C42	Joukov <i>et al.</i> , "Proteolytic Processing Regulates Receptor Specificity and Activity of VEGFR-C," <i>EMBO J.</i> , 16(13): 3898-3911 (1997).
	C43	Joukov <i>et al.</i> , "A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities," <i>J. Biol. Chem.</i> , 273(12): 6599-6602 (March, 1998).
	C44	Jussila <i>et al.</i> , "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells Detected by Antibodies against the Vascular Endothelial Growth Factor Receptor-3," <i>Cancer Res.</i> , 58: 1599-604 (April, 1998).
	C45	Kaipainen, A., <i>et al.</i> , "Expression of the fms-like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development," <i>Proc. Natl. Acad. Sci., USA</i> , 92: 3566-3570 (April, 1995).
	C46	Kieleczawa <i>et al.</i> , "DNA Sequencing by Primer Walking with Strings of Contiguous Hexamers," <i>Science</i> , 258:1787-1791 (December, 1992).
	C47	Kim <i>et al.</i> , "Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1," <i>J. Virol.</i> , 72(1): 811-816 (January, 1998).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

28967/35255B

Serial No.

10/661,740

INFORMATION DISCLOSURE
STATEMENT

Applicant

Ferrell et al.

Filing Date

September 12, 2003

Group

1632


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C48	Kingsman, A. & Johnson, E., "A New Generation of Gene Therapy Vectors," <i>Scrip Magazine</i> , pp. 43-46 (October 1998).
C49	Kinmonth, J.B., in Kinmonth, J.B. (ed), <i>The Lymphatics: Diseases, Lymphography and Surgery</i> . Edward Arnold Publishers: London, England (1972), pp. 82-86
C50	Korhonen et al., "Endothelial-Specific Gene Expression Directed by the <i>tie</i> Gene Promoter In Vivo," <i>Blood</i> , 86(5): 1828-1835 (1995).
C51	Kukk et al., "VEGF-C Receptor Binding and Pattern of Expression with VEGFR-3 Suggests a Role in Lymphatic Vascular Development," <i>Development</i> , 122: 3829-3837 (1996).
C52	Lehner et al., "Comparative Sequence Analysis of Human Cytomegalovirus Strains," <i>J. Clin. Microbiol.</i> , 29:2494-2502 (November, 1991).
C53	Levinson, K.L., "Linkage Analysis of Hereditary Lymphedema to Chromosome 5: Preliminary Analysis for a Genome Scan," Submitted to the Graduate Faculty of the Graduate School of Public Health in partial fulfillment of the requirements for the degree of Master of Science, University of Pittsburgh, pp. ii-vii and 1-54 (1996).
C54	Lewis et al., "Lymphedema praecox," <i>J. Ped.</i> , 104:641-648 (May, 1984).
C55	Lyon et al., "Research News," <i>Mouse News Lett.</i> 71: 26 (1984).
C56	Maxam et al., "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages," <i>Meth. Enzymol.</i> , 65: 499-560 (1977).
C57	Miller et al., "A Simple Salting Out Procedure for Extracting DNA from Human Nucleated Cells," <i>Nucleic Acids Res.</i> , 16: 1215 (1998).
C58	Milroy, W.F., "An Undescribed Variety of Hereditary Edema," <i>N.Y. Medical J.</i> , 56:505-508 (1892).
C59	Mirzabekov, A.D., "DNA Sequencing by Hybridization - a Megasequencing Method and a Diagnostic Tool?" <i>TIBTECH</i> , 12: 27-32 (January, 1994).
C60	Mohammadi et al., "Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism," <i>Cell</i> , 86:577-587 (August, 1996).
C61	Lyon et al., in: <i>Mouse News Lett.</i> 74: 96 (1986).
C62	Myers et al., "Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismatches in RNA: DNA Duplexes," <i>Science</i> , 230: 1242-1246 (1985).
C63	O'Connell, J.R. et al., "PedCheck: A Program for Identifying Marker Typing Incompatibilities in Linkage Analysis," D.E., <i>Am. J. Hum. Genet.</i> , 61:A288 (1997) (ABSTRACT).
C64	O'Connell, J.R. et al., "The VITESSE Algorithm for Rapid Exact Multilocus Linkage Analysis Via Genotype Set-Recoding and Fuzzy Inheritance," <i>Nature Genet.</i> , 11:402-408 (December, 1995).
C65	Offori et al., "Angiosarcoma in Congenital Hereditary Lymphoedema (Milroy's Disease) - Diagnostic Beacons and a Review of the Literature," <i>Clin. Exp. Dermatol.</i> , 18:174-177 (1993).
C66	Oh et al., "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," <i>Dev. Biol.</i> , 188:96-109 (1997).
C67	Ohkuma, M., "Dermal Lymph and Lymphatics," in <i>Lymph Stasis: Pathophysiology, Diagnosis and Treatment</i> , Chapter 7, CRC Press, Boca Raton, FL, pp. 157-189 (1991).
C68	Olszewski, W.L., "Chemistry of Lymph," in <i>Lymph Stasis: Pathophysiology, Diagnosis, and Treatment</i> , Chapter 10, CRC Press, Boca Raton, FL, pp. 235-258 (1991).
C69	Orita et al., "Detection of Polymorphisms of Human DNA by Gel Electrophoresis as Single-Strand Conformation Polymorphisms," <i>Proc Natl. Acad. Sci., USA</i> , 86: 2766-2770 (1989).

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 28967/35255B	Serial No. 10/661,740
INFORMATION DISCLOSURE STATEMENT		Applicant Ferrell et al.	
		Filing Date September 12, 2003	Group 1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C70	Ott, J., "Computer-simulation Methods in Human Linkage Analysis," <i>Proc. Nat. Acad. Sci., USA</i> , 86:4175-4178 (June, 1989).	
C71	Pajusola <i>et al.</i> , "FLT4 Receptor Tyrosine Kinase Contains Seven Immuoglobulin-Like Loops and Is Expressed in Multiple Human Tissues and Cell Lines," <i>Cancer Res.</i> , 52:5738- 5743 (October, 1992).	
C72	Pajusola <i>et al.</i> , "Two Human FLT4 Receptor Tyrosine Kinase Isoforms with Distinct Carboxy Terminal Tails are Produced by Alternative Processing of Primary Transcripts," <i>Oncogene</i> 8: 2931-2937 (1993).	
C73	Pajusola <i>et al.</i> , "Signalling Properties of FLT4, a Proteolytically Processed Receptor Tyrosine Kinase Related to Two VEGF Receptors," <i>Oncogene</i> , 9: 3545-3555 (1994).	
C74	Partanen <i>et al.</i> , "Opposite pheotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for <i>Fgfr1</i> in anteroposterior patterning of mouse embryos," <i>Genes & Development</i> , 12: 2332-2344 (1998)	
C75	Pastinen <i>et al.</i> , "Minisequencing: A Specific Tool for DNA Analysis and Diagnostics on Oligonucleotide Arrays," <i>Genome Res.</i> , 7: 606-614 (1997).	
C76	Patterson <i>et al.</i> , "Hereditary Lymphedema," <i>Comparative Pathology Bulletin</i> , 3: 2 (May, 1971).	
C77	Paulsson <i>et al.</i> , "The Balbiani Ring 3 Gene in Chironomous tentans has a Diverged Repetitive Structure Split by Many Introns," <i>J. Mol. Biol.</i> , 211:331-49 (1990).	
C78	Pease <i>et al.</i> , "Light-generated Oligonucleotide Arrays for Rapid DNA Sequence Analysis," <i>Proc. Natl. Acad. Sci., USA</i> , 91:5022-5026 (May, 1994).	
C79	Quantin <i>et al.</i> , "Adenovirus as an Expression Vector in Muscle Cells <i>in Vivo</i> ," <i>Proc. Natl. Acad. Sci., USA</i> , 89:2581-2584 (April, 1992).	
C80	Ramsay, G., "DNA Chips: State-of -the-Art," <i>Nature Biotechnology</i> , 16: 40-48 (January, 1998).	
C81	Riesner <i>et al.</i> , "Temperature-gradient Gel Electrophoresis of Nucleic Acids: Analysis of Conformational Transitions, Sequence Variations, and Protein-Nucleic acid Interactions," <i>Electrophoresis</i> , 10: 377-389 (1989).	
C82	Roberts <i>et al.</i> , "Potassium Permanganate and Tetraethylammonium Chloride are a Safe and Effective Substitute for Osmium Tetroxide in Solid-Phase Fluorescent Chemical Cleavage of Mismatch," <i>Nucl. Acids Res.</i> , 25: 3377-3378 (1997).	
C83	Rosenfeld <i>et al.</i> , "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium," <i>Cell</i> , 68: 143-155 (January, 1992).	
C84	Rowley <i>et al.</i> , "Ultrarapid Mutation Detection by Multiplex Solid-Phase Chemical Cleavage," <i>Genomics</i> , 30: 574-582 (1995).	
C85	Sambrook <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> (Second ed., Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989) §§ 9.47-9.51.	
C86	Sanger <i>et al.</i> , "DNA Sequencing With Chain-Terminating Inhibitors," <i>Proc. Natl. Acad. Sci. (USA)</i> , 74:5463-5467 (December, 1977).	
C87	Schafer <i>et al.</i> , "DNA Variation and the Future of Human Genetics," <i>Nature Biotechnology</i> , 16: 33-39 (1998).	
C88	Drmanac, R. <i>et al.</i> , "DNA sequence determination by hybridization: a strategy for efficient large-scale sequencing," [published erratum appears in <i>Science</i> 1994 Feb 4; 163(5147):596] <i>Science (UNITED STATES)</i> , 260(5114):1649-52 (June, 1993).	
C89	Shumaker <i>et al.</i> , "Mutation Detection by Solid Phase Primer Externsion," <i>Human Mutation</i> , 7: 346-354 (1996).	
C90	Stratford-Perricadet <i>et al.</i> , "Widespread Long-term Gene Transfer to Mouse Skeletal Muscles and Heart," <i>J. Clin. Invest.</i> , 90: 626-630 (August, 1992).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

28967/35255B

Serial No.

10/661,740

Applicant

Ferrell et al.

Filing Date

September 12, 2003

Group

1632

INFORMATION DISCLOSURE
STATEMENT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C91	Thompson <i>et al.</i> , "The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis," <i>Dev. Biol.</i> , 197:248-269 (1998).
C92	Tsurumi, Y. <i>et al.</i> , "Direct Intramuscular Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor Augments Collateral Development and Tissue Perfusion," <i>Circulation</i> , 34:3281-3290 (1996).
C93	Tsurumi, Y. <i>et al.</i> , "Treatment of Acute Limb Ischemia by Intramuscular Injection of Vascular Endothelial Growth Factor Gene," <i>Circulation</i> , 96(Suppl. II):II-382-II-388 (1997).
C94	Uhley, H. and Leeds, S., "Pulmonary Lymph and Lymphatics," in <i>Lymph Stasis: Pathophysiology, Diagnosis and Treatment</i> , Chapter 8, CRC Press, Boca Raton, FL, pp. 191-209 (1991).
C95	Van Der Geer <i>et al.</i> , "Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," <i>Ann. Rev. Cell. Biol.</i> , 10:251-337 (1994).
C96	van der Putte, "Congenital Hereditary Lymphedema in the Pig," <i>Lympho</i> , 11: 1-9 (1978)
C97	Weeks <i>et al.</i> , "SLINK: A General Simulation Program for Linkage Analysis," <i>Am. J. Hum. Genet.</i> , 47:A204 (1990) (ABSTRACT).
C98	Wheeler <i>et al.</i> , "Familial Lymphedema Praecox: Meige's Disease," <i>Plastic Reconstructive Surg.</i> , 67:362-364 (1981).
C99	White <i>et al.</i> , "Detecting Single Base Substitutions as Heteroduplex Polymorphisms," <i>Genomics</i> , 12: 301-306 (1992).
C100	Witte <i>et al.</i> , "Phenotypic and genotypic heterogeneity in familial Milroy lymphedema," <i>Lymphology</i> , 31(4):145-155 (1998).
C101	Yin <i>et al.</i> , "Genomic Structure of the Human KDR/flk-1 Gene," <i>Mammalian Genome</i> , 9: 408-410 (1998).
C102	Kaipainen <i>et al.</i> , "The Related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cell," <i>J. Exp. Med.</i> , 178:2077-2088 (1993).
C103	Lymboussaki <i>et al.</i> , "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors." <i>Am. J. Pathol.</i> , 153:395-403 (1998).
C104	Partanen <i>et al.</i> , "Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors." <i>Cancer</i> , 86:2406-12 (1999).
C105	Ruohola <i>et al.</i> , "Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells," <i>Mol. Cell. Endocrinol.</i> , 149:29-40 (1999).
C106	Taipale <i>et al.</i> , "Vascular endothelial growth factor receptor-3", <i>Curr. Top. Microbiol. Immunol.</i> , 237: 85-96 (1999).
C107	Valtola <i>et al.</i> , "VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer," <i>Amer. J. Pathol.</i> , 154:3801-90 (1999).
C108	Kimak <i>et al.</i> , "Linkage and mutation in the vascular endothelial growth factor-C receptor (FLT4) gene in hereditary lymphedema." <i>American J. Human Genetics</i> , 63(supplement):A34 (1998) Abstract 180
C109	Lawrence <i>et al.</i> , "Vascular endothelial growth factor-C: Genomic organization, sequence and variation." <i>American J. Human Genetics</i> , 63(supplement):A185, (October 1998) Abstract 1053.
C110	Ahern, H., "Biochemical, Reagent Kits Offer Scientists Good Return on Investment," www.thescientist.library.upenn.edu/yr1995/july/tools-950724.html
C111	Gene Characterization Kits, 1998 Stratagene Catalogue, pp 39-40.
C112	Ding <i>et al.</i> , "A Single Amino Acid Determines the Immunostimulatory Activity of Interleukin 10, <i>J. Exp. Med.</i> , 191:213-224 (2000).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.